Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Neurology|November 27, 2024
Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database studyFabian Föttinger, Nik Krajnc, Katharina Riedl, et al.
Acta Neuropathologica Communications|November 9, 2022
A case of primary optic pathway demyelination caused by oncocytic oligodendrogliopathy of unknown originSimon Hametner, Sara Silvaieh, Majda Thurnher, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 20, 2025
Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosisNik Krajnc, Markus Ponleitner, Fabian Föttinger, et al.
Frontiers in Neurology|May 1, 2024
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MSTobias Zrzavy, Kerstin Rieder, Viktoria Wuketich, et al.
Neurology|July 3, 2023
Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple SclerosisGabriel Bsteh, Harald Hegen, Patrick Altmann, et al.
Neurology|September 29, 2025
Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple SclerosisGabriel Bsteh, Harald Hegen, Nik Krajnc, et al.
European Journal of Neurology|January 31, 2023
Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosisGabriel Bsteh, Harald Hegen, Patrick Altmann, et al.
Annals of Clinical and Translational Neurology|December 17, 2024
Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical thresholdGabriel Bsteh, Harald Hegen, Nik Krajnc, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 7, 2024
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining conceptGabriel Bsteh, Harald Hegen, Nik Krajnc, et al.
European Journal of Neurology|December 28, 2020
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC scoreGabriel Bsteh, Harald Hegen, Katharina Riedl, et al.
Pageof 4